SecBot SecBot
SECBOTREPLAY Home › Report › VOR

VOR · Vor Biopharma announced that China's NMPA conditionally approved…

Vor Biopharma · PRESS-RELEASE filed Jun 8, 2026 at 08:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 8, 2026 at 08:30 ET

Vor Biopharma announced that China's NMPA conditionally approved telitacicept for IgA nephropathy, the first BAFF/APRIL-targeting therapy approved for IgAN globally. This is a major regulatory milestone that validates the drug's mechanism and supports Vor Bio's global development plans, though Vor Bio only holds ex-Greater China rights and the approval is in China, not the US/EU.

  • NMPA conditionally approved telitacicept for adult IgAN patients
  • First and only approved BAFF/APRIL-targeting therapy for IgAN
  • Approval supported by Phase 3 TELIGAN trial: 59% UPCR reduction from baseline at Week 39, 55% placebo-adjusted reduction
  • eGFR remained stable on telitacicept vs decline in placebo arm

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access